Lacosamida Intas

Lacosamide, the active ingredient in Lacosamida Intas, is a sodium channel blocker presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy. The medication works by stabilizing neuronal membranes and reducing hyperexcitability, helping to control seizure activity.

GNH USA supplies Lacosamida Intas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Lacosamide is used as an anticonvulsant in the management of seizure disorders.

Partial‑onset seizures: reduces frequency and severity of seizures when used as adjunct therapy. Epilepsy: contributes to overall seizure control in patients with focal epilepsy. Adjunctive therapy for refractory focal epilepsy: provides additional seizure reduction when combined with other antiepileptic drugs.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Nausea - Fatigue - Blurred vision - Diplopia

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Cardiac arrhythmias, including PR‑interval prolongation - Suicidal thoughts or behavior - Severe hepatic injury - Blood dyscrasias such as agranulocytosis

When prescribing Lacosamide, clinicians should consider several safety aspects. - Renal impairment: adjust dose and monitor renal function. - Hepatic impairment: use with caution and monitor liver enzymes. - Cardiac conduction abnormalities: obtain baseline ECG and monitor for PR‑interval changes. - Pregnancy: safety category unknown; weigh benefits against potential risks. - Concomitant use with other sodium channel blockers: increased risk of toxicity. - Store at ambient temperature: keep in the original pack, protect from moisture.

Lacosamide can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may lower lacosamide plasma levels. - Other sodium channel blockers (e.g., phenytoin, carbamazepine): may increase risk of cardiac and neurologic adverse effects. - QT‑prolonging agents: may heighten arrhythmia risk.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce hormonal efficacy. - Alcohol: can enhance central nervous system depression. - Combination with other antiepileptics: may require dose adjustments based on clinical response.